TX-BLUE-YONDER
1.8.2024 17:13:29 CEST | Business Wire | Press release
Blue Yonder, the leader in digital supply chain transformations, today announced the closing of its acquisition of One Network Enterprises (One Network) at an enterprise value of approximately $839 million. The acquisition gives Blue Yonder customers the ability to collaborate and share data – from inventory levels to raw and finished goods materials movement – in real time across all trading partners up and down the supply chain.
With increasing volatility and continuous disruptions, retailers, manufacturers and logistics service providers (LSPs) need to achieve multi-enterprise transparency with trading partners, unify plans and actions, and conduct business in real time in order to enable more accurate cross-functional decision-making and eliminate the time gap between order planning and fulfillment. It’s no longer sufficient for companies to rely on periodic updates about their inventory, capacity, and resources; true business agility requires real-time information across an entire network.
With the addition of One Network’s commercial technology, Blue Yonder can now offer customers a multi-enterprise, multi-tier network ecosystem; artificial intelligence (AI)-powered supply chain assistants to identify, monitor, analyze, and resolve problems; and a simplified process to onboard and work with trading partners. Real-time inventory and capacity views help customers match supply and demand, detect and resolve problems, and orchestrate resources across their network of trading partners. One Network will continue to independently service and provide tailored technology solutions to its government customers.
“One Network’s industry-leading commercial technology will seamlessly be integrated into the Blue Yonder Platform. Their supply chain network and intelligent control tower deliver superpowered insights to businesses looking to fortify their supply chains,” said Duncan Angove, CEO, Blue Yonder. “Our customers can boost visibility, agility and speed thanks to a single source of truth provided by the Blue Yonder Platform and the digital network, all enhanced by our AI assistants, solvers and predictions. This allows customers to see issues both downstream and upstream in real time, so they can avoid disruptions and make better decisions. From One Network’s capabilities to its forward-looking mission, the company perfectly embodies Blue Yonder’s vision to transform the supply chain.”
With this acquisition, Blue Yonder customers will be able to address volatility and disruptions in the market, plan with greater accuracy, meet rising customer expectations, and simplify complexity within their supply chains. Blue Yonder customers will have access to the following benefits:
- Navigating increasing uncertainty and volatility with real-time visibility across multiple tiers to anticipate risks, assess scenarios, and instantly redirect resources where needed most to deliver the greatest impacts to their business and sustainability goals.
- Optimizing of resources, from capacity and inventory to workforce and carriers to better serve their business customers, capitalize on new market opportunities, and accelerate revenue growth.
- Collaborating and orchestrating of their supply chain in real-time across a global network of 150,000 (and counting) trading partners using a shared view and dataset that ensures planning objectives flow into execution and vice versa to optimize critical KPIs.
“Blue Yonder is building the supply chain of the future,” said Angove. “To succeed in today’s business environment, planning and logistics teams need to make decisions faster. They need to collaborate with more partners. They need faster responsiveness to disruptions. One Network’s multi-tier and multi-enterprise network has a large role to play here, and we’re proud to join forces with them to make a lasting difference.”
This acquisition also catalyzed Blue Yonder’s expanded presence in Dallas, where it has been hiring extensively to support its momentum. Blue Yonder is now designating Dallas as its Global Innovation Center. In May during its annual customer conference, ICON, Blue Yonder announced a new AI Innovation Studio in Dallas where the company is hosting design-led AI Agent workshops with customers. Blue Yonder also plans to add a state-of-the-art Customer Experience Center in Dallas where the company will showcase its latest innovations that are transforming complex global supply chains.
One Network is the third company Blue Yonder has acquired since Q4 2023, following Doddle in November 2023 and flexis AG in February. These deals mark approximately $1 billion in M&A investments and are emblematic of Blue Yonder’s intent to transform the global supply chain.
About Blue Yonder
Blue Yonder is the world leader in digital supply chain transformation. Global retailers, manufacturers and logistics providers leverage Blue Yonder to optimize their supply chains from planning through fulfillment, delivery and returns. Blue Yonder’s AI-embedded, interoperable supply chain solutions are connected end-to-end via a unified platform and data cloud, enabling business to collaborate in real time across functions, which supports more agile decision-making, improved customer satisfaction, profitable growth, and more resilient, sustainable supply chains. Blue Yonder - Fulfill your PotentialTM www.blueyonder.com
“Blue Yonder” is a trademark or registered trademark of Blue Yonder Group, Inc. Any trade, product or service name referenced in this document using the name “Blue Yonder” is a trademark and/or property of Blue Yonder Group, Inc. All other company and product names may be trademarks, registered trademarks or service marks of the companies with which they are associated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240731317929/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
